Vertex Pharmaceuticals Incorporated (VRTX)
| Market Cap | 122.26B |
| Revenue (ttm) | 10.19B |
| Net Income (ttm) | 4.02B |
| Shares Out | 258.05M |
| EPS (ttm) | 15.41 |
| PE Ratio | 30.74 |
| Forward PE | 27.81 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 777,937 |
| Open | 469.76 |
| Previous Close | 471.25 |
| Day's Range | 467.41 - 477.93 |
| 52-Week Range | 335.82 - 486.43 |
| Beta | 0.41 |
| Analysts | Buy |
| Price Target | 455.45 (-3.87%) |
| Earnings Date | Aug 1, 2024 |
About VRTX
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underl... [Read more]
Financial Performance
In 2023, VRTX's revenue was $9.87 billion, an increase of 10.51% compared to the previous year's $8.93 billion. Earnings were $3.62 billion, an increase of 8.96%.
Financial StatementsAnalyst Forecast
According to 26 analysts, the average rating for VRTX stock is "Buy." The 12-month stock price forecast is $455.45, which is a decrease of -3.87% from the latest price.
News
Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for investigati...
Vertex to Announce Second Quarter 2024 Financial Results on August 1
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2024 financial results on Thursday, August 1, 2024 after the financial markets close. The com...
This Vertex Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag...
Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today presented new data from its Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differenti...
Final Trades: Nvidia, Abbvie, ConocoPhillips and Vertex Pharma
The Investment Committee share their top stocks to watch for the second half.
Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the 2024 Annual European Hematology Association (EHA) Congress
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVY™ (exagamglogene autotemcel [exa-cel]) from global clinical trials in people wit...
Vertex Shares Rising on Expanded Therapy Offerings
Global biotechnology company Vertex Pharmaceuticals Incorporated (VRTX) is a market-beating outlier stock.
Vertex Presents New Data at the European Cystic Fibrosis Conference Demonstrating Significant Benefits of Treatment with TRIKAFTA®
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that data on TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), also known in the European Union an...
Vertex to Participate in Upcoming June Investor Conferences
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences. Dr. Reshma Kewalramani, Chief Executive Offic...
Final Trades: Walmart, Vertex and the SMH
The Investment Committee gives you their top stocks to watch for the second half.
Jennifer Schneider Elected to Vertex Board of Directors
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Jennifer Schneider, M.D., M.S., has been elected to its Board of Directors as an independent director. ...
Final Trades: Pfizer, Vertex, Freeport-McMoran and Qualcomm
The Investment Committee give you their top stocks to watch for the second half.
Trade Tracker: The Committee shares some of their buys and sells
The Investment Committee discussestheir latest portfolio moves.
Vertex Is Writing A New Playbook For Pharma R&D. And It's Working.
Vertex Pharmaceuticals (NDAQ: VRTX) stands today as a top 20 pharma company with over a $100 billion market cap. But this biotech beacon has ridden a bumpy path to its current perch and, along the way...
Alpine Immune Sciences Reports First Quarter 2024 Financial Results
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseas...
Vertex tops Q1 profit estimates on robust demand for cystic fibrosis treatments
Vertex Pharmaceuticals beat Wall Street estimates for first-quarter profit on Monday, driven by robust uptake for its cystic fibrosis treatments.
Vertex Reports First Quarter 2024 Financial Results
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2024, and reiterated full year 2024 fina...
ALPINE IMMUNE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alpine Immune Sciences, Inc. - ALPN
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Alpine Immune Sc...
Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older
LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of i...
VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
Vertex obtains an exclusive license to TreeFrog's C-StemTM manufacturing technology in type 1 diabetes TreeFrog and Vertex to collaborate on scale-up of fully differentiated, insulin-producing pancr...
Vertex's stock climbs as non-opioid pain treatment advances
Vertex Pharmaceuticals Inc. shares gained ground early Thursday after the company signaled progress in the development of its experimental non-opioid pain treatment.
Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced important advancements across its suzetrigine pain program, which has the potential to be the first new clas...
Vertex Pharmaceuticals to Buy Alpine Immune in $4.9B Deal
The acquisition is a bet on a drug under development to treat the kidney condition IgA nephropathy.
Vertex may have to pay more than $65 for Alpine Immune stock ($ALPN)
Alpine Immune Sciences Inc (NASDAQ: ALPN) is up 35% on Thursday after Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) said it will acquire the biotechnology company for $65 per share. Is Alpine Imm...